Hyperdynamic circulation in portal hypertension: A comparative model of arterio-venous fistula

Medical Hypotheses

Volumn 55, Issue 1, 2000, Pages 77-87

  Wattanasirichaigoon, S ^a   Gordon, F D ^b   Resnick, R H ^b  

^a SRINAKHARINWIROT UNIVERSITY   (Thailand)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NITRIC OXIDE SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; HEART OUTPUT; HEMODYNAMICS; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; PRIORITY JOURNAL; RAT;

ANIMALIA; FISTULA;

EID: 0033868262     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1999.1034     Document Type: Article

References (114)

1. Geraghty J. G., Angerson W. J., Carter D. C. Portal venous pressure and portasystemic shunting in experimental portal hypertension. Am J Physiol. 257:1989;G52-57.
2. Colombato L. A., Albillos A., Groszmann R. J. The role of central blood volume in the development of sodium retention in portal hypertensive rats. Gastroenterology. 110:1996;193-198.
3. Guarner C., Soriano G., Tomas A. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology. 18:1993;1139-1143.
4. Fernandez M., Garcia-Pagan J. C., Casadevall M. Evidence against a role for inducible nitric oxide synthase in the hyperdynamic circulation of portal-hypertensive rats. Gastroenterology. 108:1995;1487-1495.
5. Benoit J. N., Zimmerman B., Premen A. J. Role of glucagon in splanchnic hyperemia of chronic portal hypertension. Am J Physiol. 251:1986;G674-677.
6. Lopez-Talavera J. C., Merrill W. W., Groszmann R. J. Tumor necrosis factor alpha: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology. 108:1995;761-767.
7. Keratopanis S., McCormick P. A., Jacobs M. Role of nitric oxide in the altered systemic vascular reactivity in portal vein contricted rats. J Hepatol. 16:1992;S-34.
8. Hori N., Takahashi H., Okanoue T. Augmented endogenous nitric oxide production in partial portal vein-ligated rats. Clin Exp Pharmacol Physiol. 22:1995;506-511.
9. Pilette C., Kirstetter P., Sogni P. Dose-dependent effects of a nitric oxide biosynthesis inhibitor on hyperdynamic circulation in two models of portal hypertension in conscious rats. J Gastroenterol Hepatol. 11:1996;1-6.
10. Aranow J. S., Wang H., Zhuang J. Effect of human hemoglobin on systemic and regional hemodynamics in a porcine model of endotoxemic shock. Crit Care Med. 24:1996;807-814.
11. Cambria R. A., Lowell R. C., Gloviczki P. Chronic changes in blood flow alter endothelium-dependent responses in autogenous vein grafts in dogs. J Vasc Surg. 20:1994;765-773.
12. Nadaud S., Philippe M., Arnal J. F. Sustained increase in aortic endothelial nitric oxide synthase expression in vivo in a model of chronic high blood flow. Circ Res. 79:1996;857-863.
13. Anand I. S., Chandrashekhar Y., Wander G. S. Endothelium-derived relaxing factor is important in mediating the high output state in chronic severe anemia. J Am Coll Cardiol. 25:1995;1402-1407.
14. Summer, D. S. Hemodynamics and Pathophysiology of Arteriovenous Fistulas. Philadelphia, WB Saunders, 1995.
15. Ingles A. C., Legare D. J., Lautt W. W. Development of portacaval shunts in portal-stenotic cats. Can J Physiol Pharmacol. 71:1993;671-674.
16. Khaliq S. U., Kay J. M., Heath D. Porta-pulmonary venous anastomoses in experimental cirrhosis of the liver in rats. J Pathol. 107:1972;167-174.
17. Oberti F., Rifflet H., Maiga M. Y. Prevention of portal hypertension by propranolol and spironolactone in rats with bile duct ligation. J Hepatol. 26:1997;167-173.
18. Koyanagi N., Inokuchi K., Nakayama S. Decreased arteriovenous flow resistance in the left gastric venous area in cirrhotic patients. Eur J Clin Invest. 11:1981;355-359.
19. Waddell W. G., Bouchard A. G., Wellington J. L. Functional relations of the proximal portal components studied by different outflow-tract manipulations. Can J Surg. 16:1973;155-168.
20. Lee F. Y., Colombato L. A., Albillos A. Administration of N omega-nitro-L-arginine ameliorates portal-systemic shunting in portal-hypertensive rats. Gastroenterology. 105:1993;1464-1470.
21. Lin H. C., Soubrane O., Cailmail S. Early chronic administration of propranolol reduces the severity of portal hypertension and portal-systemic shunts in conscious portal vein stenosed rats. J Hepatol. 13:1991;213-219.
22. Sarin S. K., Groszmann R. J., Mosca P. G. Propranolol ameliorates the development of portal-systemic shunting in a chronic murine schistosomiasis model of portal hypertension. J Clin Invest. 87:1991;1032-1036.
23. Takashi M., Igarashi M., Hino S. Esophageal varices: correlation of left gastric venography and endoscopy in patients with portal hypertension. Radiology. 155:1985;327-331.
24. Holland, P. D. J. Inflammation. Phaladelphia, WB Saunders, 1974.
25. Rabinovici N., Navot N. The relationship between respiration, pressure and flow distribution in the vena cava and portal and hepatic veins. Surg Gynecol Obstet. 151:1980;753-763.
26. Abu-Yousef M. M. Normal and respiratory variations of the hepatic and portal venous duplex Doppler waveforms with simultaneous electrocardiographic correlation. J Ultrasound Med. 11:1992;263-268.
27. Moreno A. H., Burchell A. R. Respiratory regulation of splanchnic and systemic venous return in normal subjects and in patients with hepatic cirrhosis. Surg Gynecol Obstet. 154:1982;257-267.
28. Kimura T., Moriyasu F., Kawasaki T. relationship between esophageal varices and azygos vein evaluated by cineportography. Hepatology. 13:1991;858-864.
29. Hayes P. C., Terrace D., Peaston I. Computerised system for the continuous measurement of azygos venous blood flow. Gut. 33:1992;372-374.
30. Hosking S. W., Robinson P., Johnson A. G. Effect of Valsalva's manoeuvre and hyoscinbutylbromide on the pressure gradient across the wall of oesophageal varices. Gut. 28:1987;1151-1156.
31. Lomas D. J., Hayball M. P., Jones D. P. Non-invasive measurement of azygos venous blood flow using magnetic resonance. J Hepatol. 22:1995;399-403.
32. Schraufnagel D. E., Kay J. M. Structural and pathologic changes in the lung vasculature in chronic liver disease. Clin Chest Med. 17:1996;1-15.
33. Wattanasirichaigoon S., Tang I. M., Harris A. G. Why do varices develop preferrentially in the esophagus in portal hypertensive patients?: a hypothesis based on cardiopulmonary physiology. J Med Assoc Thai. 77:1994;534-538.
34. Del Guercio L. R. M., Commaraswamy R. P., Feins N. R. Pulmonary arteriovenous admixture and the hyperdynamic cardiovascular state in surgery for portal hypertension. Surgery. 56:1964;57-74.
35. Johnson G. Jr, Dart C. H. Jr, Peters R. M. Hemodynamic changes with cirrhosis of the liver: control of arteriovenous shunts during operation for esophageal varices. Ann Surg. 163:1966;692-703.
36. Krowka M. J. Hepatopulmonary syndrome versus portopulmonary hypertension: distinctions and dilemmas [editorial; comment]. Hepatology. 25:1997;1282-1284.
37. Castro M., Krowka M. J. Hepatopulmonary syndrome. A pulmonary vascular complication of liver disease. Clin Chest Med. 17:1996;35-48.
38. Rodriguez-Roisin R., Agusti A. G., Roca J. The hepatopulmonary syndrome: new name, old complexities [editorial]. Thorax. 47:1992;897-902.
39. Fernadez-Rodriguez C. M., Prieto J., Zozaya J. M. Arteriovenous shunting, hemodynamic changes, and renal sodium retention in liver cirrhosis. Gastroenterology. 104:1993;1139-1145.
40. Mehta R., Gottstein J., Zeller W. P. Endotoxin and the hyperdynamic circulation of portal vein-ligated rats. Hepatology. 12:1990;1152-1156.
41. Nicholls K. M., Shapiro M. D., Van Putten V. J. Elevated plasma norepinephrine concentrations in decompensated cirrhosis. Association with increased secretion rates, normal clearance rates, and suppressibility by central blood volume expansion. Circ Res. 56:1985;457-461.
42. Blanchet L., Lebrec D. Changes in splanchnic blood flow in portal hypertensive rats. Eur J Clin Invest. 12:1982;327-330.
43. Vorobioff J., Bredfeldt J. E., Groszmann R. J. Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol. 244:1983;G52-57.
44. Ma Z., Lee S. S. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology. 24:1996;451-459.
45. Moriyasu F., Nishida O., Ban N. Measurement of portal vascular resistance in patients with portal hypertension. Gastroenterology. 90:1986;710-717.
46. Murray J. F., Dawson A. M., Sherlock S. Circulatory changes in chronic liver disease. Am J Med. 32:1958;358-367.
47. Siegel J. H., Goldwyn R. M., Farrell E. J. Hyperdynamic states and the physiologic determinants of survival in patients with cirrhosis and portal hypertension. Arch Surg. 108:1974;282-292.
48. Colombato L. A., Spahr L., Martinet J. P. Haemodynamic adaptation two months after transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients. Gut. 39:1996;600-604.
49. Lee S. S., Johansen K., Lebrec D. Circulatory changes inducted by portal venous diversion and mesenteric hypertension in rats. Hepatology. 15:1992;117-121.
50. Sikuler E., Groszmann R. J. Hemodynamic studies in long- and short-term portal hypertensive rats: the relation to systemic glucagon levels. Hepatology. 6:1986;414-418.
51. Schwartz, S. I. Liver. New York, McGraw-Hill, 1989.
52. Wong J., Zhang Y., Lee S. S. Effects of portacaval shunting on hyperdynamic circulation in bile duct-ligated cirrhotic rats. J Hepatol. 26:1997;369-375.
53. Fallon M. B., Abrams G. A., Luo B. The role of endothelial nitric oxide synthase in the pathogenesis of a rat model of hepatopulmonary syndrome [see comments]. Gastroenterology. 113:1997;606-614.
54. Ohno T., Branch R. A., Sabra R. Sodium retention and hepatic function following partial portal vein ligation in the rat. J Hepatol. 18:1993;235-243.
55. Schrier R. W., Arroyo V., Bernardi M. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis [see comments]. Hepatology. 8:1988;1151-1157.
56. Lee F. Y., Colombato L. A., Albillos A. N omega-nitro-L-arginine administration corrects peripheral vasodilation and systemic capillary hypotension and ameliorates plasma volume expansion and sodium retention in portal hypertensive rats. Hepatology. 17:1993;84-90.
57. Thompson E. N., Willims R., Sherlock S. Liver function in extrahepatic portal hypertension. Lancet. ii:1964;1352-1356.
58. Rockey D. The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. Hepatology. 25:1997;2-5.
59. Rockey D. C., Chung J. J. Regulation of inducible nitric oxide synthase during liver injury [Abstract]. Hepatology. 22:1995;249A.
60. Wensing G., Sabra R., Branch R. A. Renal and systemic hemodynamics in experimental cirrhosis in rats: relation to hepatic function. Hepatology. 12:1990;13-19.
61. Gerbes A. L., Arendt R. M., Ritter D. Plasma atrial natriuretic factor in patients with cirrhosis [letter]. N Engl J Med. 313:1985;1609-1610.
62. Rector W. G. Jr, Adair O., Hossack K. F. Atrial volume in cirrhosis: relationship to blood volume and plasma concentration of atrial natriuretic factor. Gastroenterology. 99:1990;766-770.
63. Michielsen P. P., Boeckxstaens G. E., Sys S. U. The role of increased nitric oxide in the vascular hyporeactivity to noradrenaline in long-term portal vein ligated rats. J Hepatol. 23:1995;341-347.
64. Ryan J., Sudhir K., Jennings G. Impaired reactivity of the peripheral vasculature to pressor agents in alcoholic cirrhosis. Gastroenterology. 105:1993;1167-1172.
65. Sieber C. C., Groszmann R. J. Nitric oxide mediates hyporeactivity to vasopressors in mesenteric vessels of portal hypertensive rats. Gastroenterology. 103:1992;235-239.
66. Naeiji R., Hallemans R., Mols P. Hypoxic pulmonary vasoconstrictor in liver cirrhosis. Chest. 80:1981;570-574.
67. Miller V. M., Burnett J. C. Jr Modulation of NO and endothelin by chronic increases in blood flow in canine femoral arteries. Am J Physiol. 263:1992;H103-108.
68. Liao J. F., Yu P. C., Lin H. C. Study on the vascular reactivity and alpha 1-adrenoceptors of portal hypertensive rats. Br J Pharmacol. 111:1994;439-444.
69. Heinemann A., Stauber R. E. The role of inducible nitric oxide synthase in vascular hyporeactivity of endotoxin-treated and portal hypertensive rats. Eur J Pharmacol. 278:1995;87-90.
70. Bichet D. G., Van Putten V. J., Schrier R. W. Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis. N Engl J Med. 307:1982;1552-1557.
71. Ring-Larsen H., Hesse B., Henriksen J. H. Sympathetic nervous activity and renal and systemic hemodynamics in cirrhosis: plasma norepinephrine concentration, hepatic extraction, and renal release. Hepatology. 2:1982;304-310.
72. Fattovich G., Giustina G., Degos F. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients [see comments]. Gastroenterology. 112:1997;463-472.
73. Bender, M. D. Ockner, R. K. Ascites. Philadelphia, WB Saunders, 1989.
74. Genecin, P. Groszmann, R. J. Portal Hypertension, Philadelphia, JB Lippincott, 1993.
75. Epstein, M. Functional Renal Abnormalities in Cirrhosis: Pathophysiology and Management. Philadelphia, WB Saunders, 1990.
76. Gann, D. S. Foster, A. H. Endocrine and Metabolic Responses to Injury. New York, McGraw-Hill, 1994.
77. Sawchenko P. E., Friedman M. I. Sensory functions of the liver - a review. Am J Physiol. 236:1979;R5-20.
78. Kostreva D. R., Castaner A., Kampine J. P. Reflex effects of hepatic baroreceptors on renal and cardiac sympathetic nerve activity. Am J Physiol. 238:1980;R390-394.
79. Martinet J. P., Legault L., Cernacek P. Changes in plasma endothelin-1 and Big endothelin-1 induced by transjugular intrahepatic portosystemic shunts in patients with cirrhosis and refractory ascites. J Hepatol. 25:1996;700-706.
80. Wong F., Sniderman K., Liu P. The mechanism of the initial natriuresis after transjugular intrahepatic portosystemic shunt. Gastroenterology. 112:1997;899-907.
81. Wong F., Sniderman K., Liu P. Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann Intern Med. 122:1995;816-822.
82. Sanyal A. J., Freedman A. M., Luketic V. A. The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts [comment] [see comments]. Gastroenterology. 112:1997;889-898.
83. Grace N. D. TIPS: the long and short of it [editorial] [see comments]. Gastroenterology. 112:1997;1040-1043.
84. Rossle M., Haag K., Blum H. E. The transjugular intrahepatic portosystemic stent-shunt: a review of the literature and own experiences. J Gastroenterol Hepatol. 11:1996;293-298.
85. Ohnishi K., Nakayama T., Koen H. Interrelationship between type of spontaneous portal systemic shunt and portal vein pressure in patients with liver disease. Am J Gastroenterol. 80:1985;561-564.
86. Zoli M., Magalotti D., Bianchi G. Functional hepatic flow and Doppler-assessed total hepatic flow in control subjects and in patients with cirrhosis. J Hepatol. 23:1995;129-134.
87. Rector W. G. Jr, Hoefs J. C., Hossack K. F. Hepatofugal portal flow in cirrhosis: observations on hepatic hemodynamics and the nature of the arterioportal communications. Hepatology. 8:1988;16-20.
88. Burchell H. B. Observations on bradycardia produced by occlusion of an artery proximal to an arteriovenous fistula (Nicolandoni-Branham sign). Med Clin North Am. 42:1958;1029-1035.
89. Wattansirichaigoon S., Pomposelli F. B. Jr Branham's sign is an exaggerated Bezold-Jarisch reflex of arteriovenous fistula [letter]. J Vasc Surg. 26:1997;171-172.
90. Hayes P. C., Davis J. M., Lewis J. A. Meta-analysis of value of propranolol in prevention of variceal haemorrhage [published erratum appears inLancet 1990 Aug 4;336 (8710): 324] [see comments]. Lancet. 336:1990;153-156.
91. Bernard B., Lebrec D., Mathurin P. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology. 25:1997;63-70.
92. Lebrec D., Poynard T., Bernuau J. A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology. 4:1984;355-358.
93. Kroeger R. J., Groszmann R. J. Effect of selective blockade of beta 2-adrenergic receptors on portal and systemic hemodynamics in a portal hypertensive rat model. Gastroenterology. 88:1985;896-900.
94. Feu F., Bordas J. M., Luca A. Reduction of variceal pressure by propranolol: comparison of the effects on portal pressure and azygos blood flow in patients with cirrhosis. Hepatology. 18:1993;1082-1089.
95. Ohnishi K., Nakayama T., Saito M. Effects of propranolol on portal hemodynamics in patients with chronic liver disease. Am J Gastroenterol. 80:1985;132-135.
96. Garcia-Tsao G., Grace N. D., Groszmann R. J. Short-term effects of propranolol on portal venous pressure. Hepatology. 6:1986;101-106.
97. Cales P., Braillon A., Jiron M. I. Superior portosystemic collateral circulation estimated by azygos blood flow in patients with cirrhosis. Lack of correlation with oesophageal varices and gastrointestinal bleeding. Effect of propranolol. J Hepatol. 1:1985;37-46.
98. Vallance P., Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet. 337:1991;776-778.
99. Forrest E. H., Jones A. L., Dillon J. F. The effect of nitric oxide synthase inhibition on portal pressure and azygos blood flow in patients with cirrhosis. J Hepatol. 23:1995;254-258.
100. Lopez-Talavera J. C., Cadelina G., Olchowski J. Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portalhypertensive rats. Hepatology. 23:1996;1616-1621.
101. Lee F. Y., Wang S. S., Tsai Y. T. Aminoguanidine corrects hyperdynamic circulation without ameliorating portal hypertension and portal hypertensive gastropathy in anesthetized portal hypertensive rats. J Hepatol. 26:1997;687-693.
102. Albornoz L., Bandi J. C., Sanchez S. Dexamethasone administration does not affect hemodynamic parameters in an experimental model of cirrhosis. Gastroenterology. 106:1994;A897.
103. Garcia-Pagan J. C., Casadevall M., Fernandez M. Chronic dexamethasone does not modify the hyperdynamic circulation in portal hypertension. Gastroenterology. 104:1994;A897.
104. Tanoue K., Ohta M., Tarnawski A. S. Portal hypertension activates the nitric oxide synthase genes in the esophageal mucosa of rats. Gastroenterology. 110:1996;549-557.
105. Gadano A. C., Sogni P., Yang S. Endothelial calcium-calmodulin dependent nitric oxide synthase in the in vitro vascular hyporeactivity of portal hypertensive rats. J Hepatol. 26:1997;678-686.
106. Martin P. Y., Xu D. L., Niederberger M. Upregulation of endothelial constitutive NOS: a major role in the increased NO production in cirrhotic rats. Am J Physiol. 270:1996;F494-499.
107. Niederberger M., Martin P. Y., Gines P. Normalization of nitric oxide production corrects arterial vasodilation and hyperdynamic circulation in cirrhotic rats. Gastroenterology. 109:1995;1624-1630.
108. Pizcueta M. P., Pique J. M., Bosch J. Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension. Br J Pharmacol. 105:1992;184-190.
109. Cahill P. A., Foster C., Redmond E. M. Enhanced nitric oxide synthase activity in portal hypertensive rabbits. Hepatology. 22:1995;598-606.
110. Araujo M. T., Cabral A. M., Vasquez E. C. Exaggerated Bezold-Jarisch reflex in the hypertension induced by inhibition of nitric oxide synthesis. Braz J Med Biol Res. 28:1995;1009-1012.
111. Luca A., Garcia-Pagan J. C., Bosch J. Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis. Gastroenterology. 112:1997;1284-1289.
112. Buchman T. G. Physiologic stability and physiologic state. J Trauma. 41:1996;599-605.
113. Mosca P., Lee F. Y., Kaumann A. J. Pharmacology of portal-systemic collaterals in portal hypertensive rats: role of endothelium. Am J Physiol. 263:1992;G544-550.
114. Campillo B., Chabrier P. E., Pelle G. Inhibition of nitric oxide synthesis in the forearm arterial bed of patients with advanced cirrhosis. Hepatology. 22:1995;1423-1429.